Biohope is a R&D company dedicated to the development of precision medicine IVD tools for chronic inflammatory conditions. Biohope has received funding through the European Commission’s H2020 program, and employees 16 professionals in R&D, Medical Affairs, Financial, Legal, Quality Control and BD&L.

Our lead product, IMMUNOBIOGRAM® , is a novel, patented in vitro diagnostic device that allows the optimization of immunosuppressive therapy .

An initial, proof of concept national clinical study in kidney transplantation has demonstrated the utility of IMMUNOBIOGRAM® and a confirmatory international study is to be concluded in 2Q 2019.

In addition to its use for transplanted patients, the technology has the potential  to be used inRheumatoid Arthritis (RA),  for which a clinical study has been initiated in 2018.

“Biohope has delivered exceptional results with significant immediate or potential impact. The Beneficiary is a perfect example of a SME Instrument successful company, where hard work combined with brilliant ideas, courage and EU financing result in very promising and interesting primary results.”

(2018 European Commission Report)


Thanks to the effort and commitment of our excellent Team, several organizations and institutions have recognized our achievements. Likewise, media are increasingly picking up news about Biohope.


The National Transplant Organization of Spain, the most renowed transplant organization in Europe, supported this project to be scaled up to European scope.


This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the grant agreement Nº 733248.